公开(公告)号：SK5542001A3

公开(公告)日：2001-12-03

申请号：SK5542001

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：NO20012061D0

公开(公告)日：2001-04-26

申请号：NO20012061

申请日：2001-04-26

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06 ,  C07D

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CZ2000446A3

公开(公告)日：2000-05-17

申请号：CZ2000446

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  RHODE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CZ20000446A3

公开(公告)日：2000-05-17

申请号：CZ20000446

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  RHODE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

CPC classification number: C07D401/06 ,  C07D237/14 ,  C07D237/18 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D417/06

公开(公告)号：AU6523099A

公开(公告)日：2000-05-15

申请号：AU6523099

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

公开(公告)号：CA2347982A1

公开(公告)日：2000-05-04

申请号：CA2347982

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： LIU HUAQING ,  KOLASA TEODOZYJ ,  BASHA ANWER ,  KORT MICHAEL E ,  STEWART ANDREW O ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  MCCARTY CATHERINE M ,  COGHLAN MICHAEL J ,  BLACK LAWRENCE A

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：NO20000863L

公开(公告)日：2000-02-22

申请号：NO20000863

申请日：2000-02-22

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：AU8697698A

公开(公告)日：1999-03-16

申请号：AU8697698

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07D237/14 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/5377 ,  A61P5/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D20060101 ,  C07D237/10 ,  C07D237/16 ,  C07D237/18 ,  C07D237/20 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D417/12 ,  C07F9/547 ,  C07F9/6509 ,  C07F11/00

Abstract: In the present invention, there are described pyridazinone compounds, which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CA2299300A1

公开(公告)日：1999-03-04

申请号：CA2299300

申请日：1998-08-10

Applicant: ABBOTT LAB

Inventor： MCCARTY CATHERINE M ,  PATEL MEENA V ,  KORT MICHAEL E ,  KOLASA TEODOZYJ ,  LIU HUAQING ,  ROHDE JEFFREY J ,  BASHA ANWER ,  BLACK LAWRENCE A

IPC: C07D237/14 ,  C07D237/18 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D417/06 ,  A61K31/50 ,  C07D413/06 ,  C07F11/00

Abstract: The present invention describes pyridazinone compounds which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX/2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

公开(公告)号：CA2294548A1

公开(公告)日：1999-03-04

申请号：CA2294548

申请日：1998-08-20

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P19/10 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D237/14 ,  C07D237/18 ,  C07D237/20 ,  C07D409/04 ,  C07F9/6509

Abstract: The present invention describes pyridazinone compounds which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).